These innovative molecules represent a significant leap in the management of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in lowering blood glucose levels. https://jasontdov143349.collectblogs.com/83713824/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide